Piper Sandler analyst David Westenberg raised the firm’s price target on Cytek Biosciences to $17 from $16 and keeps an Overweight rating on the shares. The analyst updated his model to reflect the recent earnings report.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CTKB: